--- title: "Alumis (ALMS) news: class action, going concern and offering" url: "https://aibio.space/companies/alumis/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "ALMS class action, going concern, offering and merger news: Alumis carries ACELYRIN securities class action over izokibep trial; dismissal motion pending." --- ALMS Alumis Inc. NASDAQ · United States # Alumis (ALMS) news ALMS class action, going concern, offering and merger news Legal · 2026-08-13 ## [Alumis carries ACELYRIN securities class action over izokibep trial; dismissal motion pending](https://aibio.space/news/alumis-carries-acelyrin-securities-class-action-izokibep-trial/) Alumis (Nasdaq: ALMS) inherited Boukadoum v. Acelyrin in its May 2025 merger. The filing names ACELYRIN and unnamed officers and directors; ACELYRIN's 2024 signers are listed. ## Latest Alumis news 1. 2026-01-07 Financings [Alumis raises $300 million a day after psoriasis pill beats placebo and apremilast in phase 3](https://aibio.space/news/alumis-raises-300-million-day-after-psoriasis-pill-beats-placebo/) Alumis sold 17.65 million shares at $17 after two phase 3 trials of its oral TYK2 inhibitor envudeucitinib met all endpoints. A prospectus had flagged going-concern doubt before the deal. 2. 2025-05-21 Mergers [Alumis completes ACELYRIN merger at 0.4814 Alumis shares per ACELYRIN share](https://aibio.space/news/alumis-completes-acelyrin-merger-0-4814-alumis-shares-acelyrin-share/) Alumis Inc. says the merger closed May 21, 2025, making ACELYRIN a wholly owned subsidiary. Alumis says its cash runway now extends into 2027, and Lynn Tetrault joined its board. 3. 2025-05-21 Mergers [Alumis completes merger with ACELYRIN at 0.4814 shares per ACELYRIN share](https://aibio.space/news/alumis-completes-merger-acelyrin-0-4814-shares-acelyrin-share/) The closing release uses 0.4814 shares per ACELYRIN share, while the merger agreement and Alumis's annual report set 0.4274, and the release does not explain the gap. 4. 2025-02-06 Mergers [Alumis agrees to all-stock merger with ACELYRIN, with pro forma cash of about $737 million](https://aibio.space/news/alumis-agrees-all-stock-merger-acelyrin-pro-forma-cash-about-737/) ACELYRIN holders would receive 0.4274 Alumis shares for each share and own about 45% of the combined company. The cash figures behind the deal are preliminary and unaudited, and ACELYRIN's lead program is being re-evaluated. 5. 2025-02-06 Mergers [Alumis and ACELYRIN agree to all-stock merger with $737 million pro forma cash](https://aibio.space/news/alumis-acelyrin-agree-all-stock-merger-737-million-pro-forma-cash/) ACELYRIN holders would receive 0.4274 Alumis shares for each share they own, and the $737 million pro forma cash figure rests on preliminary year-end balances. ## Alumis at a glance - **Ticker**: ALMS - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $63.7 million ### Related companies - [Matinas Biopharma Holdings](https://aibio.space/companies/matinas-biopharma/) AMEX: MTNB - [Ocugen](https://aibio.space/companies/ocugen/) NASDAQ: OCGN - [Bioxytran](https://aibio.space/companies/bioxytran/) OTC: BIXT - [PDS Biotechnology](https://aibio.space/companies/pds-biotechnology/) NASDAQ: PDSB - [MacroGenics](https://aibio.space/companies/macrogenics/) NASDAQ: MGNX - [Harbor Diversified](https://aibio.space/companies/harbor-diversified/) OTC: HRBR - [Neumora Therapeutics](https://aibio.space/companies/neumora-therapeutics/) NASDAQ: NMRA - [Sonoma Pharmaceuticals](https://aibio.space/companies/sonoma-pharmaceuticals/) NASDAQ: SNOA ### Also on NASDAQ - [Autonomix Medical](https://aibio.space/companies/autonomix-medical/) AMIX - [Palvella Therapeutics](https://aibio.space/companies/palvella-therapeutics/) PVLA - [Passage Bio](https://aibio.space/companies/passage-bio/) PASG - [Bolt Biotherapeutics](https://aibio.space/companies/bolt-biotherapeutics/) BOLT - [AgomAb Therapeutics NV](https://aibio.space/companies/agomab-therapeutics/) AGMB - [Unicycive Therapeutics](https://aibio.space/companies/unicycive-therapeutics/) UNCY ## What Alumis does Alumis Inc. is a clinical-stage biopharmaceutical company developing Tyrosine Kinase 2 (TYK2) inhibitors for immune-mediated diseases. Its most advanced candidate, envudeucitinib (envu, formerly ESK-001), is an allosteric TYK2 inhibitor studied in plaque psoriasis and systemic lupus erythematosus. The company reported positive topline results from the pivotal Phase 3 ONWARD1 and ONWARD2 trials in plaque psoriasis in the first quarter of 2026, and it plans to submit a New Drug Application to the FDA in the second half of 2026. A Phase 2 lupus trial is expected to report topline results in the third quarter of 2026. A-005 is a CNS-penetrant allosteric TYK2 inhibitor intended for neuroinflammatory and neurodegenerative diseases, including multiple sclerosis, Alzheimer disease, amyotrophic lateral sclerosis and Parkinson disease. Through the ACELYRIN merger, which closed on May 21, 2025, the company also acquired lonigutamab, an IGF-1R antibody for Thyroid Eye Disease. Alumis also has earlier-stage targets, including IRF5, and says it plans to evaluate strategic collaborations for its lead programs. | Product or program | What it is | Stage | |---|---|---| | envudeucitinib (envu, ESK-001) | Second-generation allosteric TYK2 inhibitor for psoriasis and lupus | Phase 3 pivotal trials; NDA planned for second half of 2026 | | A-005 | CNS-penetrant allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases | Phase 1 program initiated April 2024 | | lonigutamab | Subcutaneously delivered monoclonal antibody targeting IGF-1R for Thyroid Eye Disease | | | IRF5 targets | Earlier-stage targets selected for broad indications | Lead identification to lead optimization | Summarised from the company's [10-K filed Mar 19, 2026](https://www.sec.gov/Archives/edgar/data/1847367/000184736726000006/alms-20251231x10k.htm). ## Alumis annual financials | Line | FY2025 | FY2024 | |---|---|---| | Revenue | [$24.1 million](https://www.sec.gov/Archives/edgar/data/1847367/000184736726000006/) | | | Research and development | [$386.0 million](https://www.sec.gov/Archives/edgar/data/1847367/000184736726000006/) | [$265.6 million](https://www.sec.gov/Archives/edgar/data/1847367/000184736726000006/) | | Net income (loss) | [-$243.3 million](https://www.sec.gov/Archives/edgar/data/1847367/000184736726000006/) | [-$294.2 million](https://www.sec.gov/Archives/edgar/data/1847367/000184736726000006/) | | Cash from operations | [-$369.5 million](https://www.sec.gov/Archives/edgar/data/1847367/000184736726000006/) | [-$255.1 million](https://www.sec.gov/Archives/edgar/data/1847367/000184736726000006/) | | Cash and equivalents | [$89.7 million](https://www.sec.gov/Archives/edgar/data/1847367/000184736726000018/) | [$169.5 million](https://www.sec.gov/Archives/edgar/data/1847367/000184736726000006/) | | Short-term investments | [$218.8 million](https://www.sec.gov/Archives/edgar/data/1847367/000184736726000006/) | [$118.7 million](https://www.sec.gov/Archives/edgar/data/1847367/000184736726000006/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $63.7 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Alumis Is there a class action against Alumis? Our latest story on this, dated Aug 13, 2026: "Alumis carries ACELYRIN securities class action over izokibep trial; dismissal motion pending". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/alumis-carries-acelyrin-securities-class-action-izokibep-trial/). Has Alumis issued a going-concern warning? Our latest story on this, dated Jan 7, 2026: "Alumis raises $300 million a day after psoriasis pill beats placebo and apremilast in phase 3". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/alumis-raises-300-million-day-after-psoriasis-pill-beats-placebo/). Has Alumis raised money recently? Our latest story on this, dated Jan 7, 2026: "Alumis raises $300 million a day after psoriasis pill beats placebo and apremilast in phase 3". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/alumis-raises-300-million-day-after-psoriasis-pill-beats-placebo/). Is Alumis involved in a merger or acquisition? Our latest story on this, dated Aug 13, 2026: "Alumis carries ACELYRIN securities class action over izokibep trial; dismissal motion pending". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/alumis-carries-acelyrin-securities-class-action-izokibep-trial/). What is the ticker symbol of Alumis? Alumis Inc. trades under the ticker ALMS on NASDAQ. Where is Alumis listed? Alumis Inc. is listed on NASDAQ. What is the SEC CIK of Alumis? The SEC Central Index Key (CIK) for Alumis Inc. is 1847367. Its filings are on SEC EDGAR. Which country or territory is Alumis listed under? Our directory records Alumis Inc. under United States. What does Alumis do? Our directory classifies Alumis Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of Alumis? The ISIN recorded for Alumis Inc. is US0223071020. Does aibio.space cover Alumis? aibio.space lists Alumis Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Alumis incorporated? SEC records list its state or country of incorporation as DE. What does Alumis develop? Alumis Inc. is a clinical-stage biopharmaceutical company developing Tyrosine Kinase 2 (TYK2) inhibitors for immune-mediated diseases. Its most advanced candidate, envudeucitinib (envu, formerly ESK-001), is an allosteric TYK2 inhibitor studied in plaque psoriasis and systemic lupus erythematosus. What is envudeucitinib (envu, ESK-001) from Alumis? envudeucitinib (envu, ESK-001): Second-generation allosteric TYK2 inhibitor for psoriasis and lupus Stage: Phase 3 pivotal trials; NDA planned for second half of 2026. What is A-005 from Alumis? A-005: CNS-penetrant allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases Stage: Phase 1 program initiated April 2024. ## Investor discussion: Alumis Members talk about Alumis (ALMS). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Alumis, newest first. Each line links the filing it comes from. 1. 2026-03-19 Financings Set up an at-the-market program to sell shares over time. SEC Form S-3ASR. [Source](https://www.sec.gov/Archives/edgar/data/1847367/000110465926032158/tm269184-1_s3asr.htm) 2. 2026-01-06 Financings Filed a final prospectus for a securities offering. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1847367/000110465926001410/tm2534587-1_424b5.htm) 3. 2025-08-13 Legal Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/1847367/000184736725000041/alms-20250630x10q.htm) 4. 2025-05-21 Mergers Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 2.01,5.02,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1847367/000110465925051338/tm2515764d1_ex99-1.htm) 5. 2025-03-19 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1847367/000184736725000012/tmb-20241231x10k.htm) 6. 2025-02-06 Mergers Reported a merger or acquisition agreement. SEC Form 8-K (Items 1.01,2.02,7.01,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1847367/000110465925010169/tm254989d1_ex99-1.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:ALMS on TradingView](https://www.tradingview.com/symbols/NASDAQ-ALMS/). ## SEC filings and registration - **SEC name**: Alumis Inc. - **CIK**: 1847367 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: ALMS (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**:
Emerging growth company - **Business address**: 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO, CA, 94080 - **Phone**: 650-231-6625 - **Former names**: FL2021-001, Inc. ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1847367/000110465926104145/tm2624540d1_8k.htm) filed 2026-09-01 - [10-Q](https://www.sec.gov/Archives/edgar/data/1847367/000184736726000018/alms-20260630x10q.htm) filed 2026-08-13 - [8-K](https://www.sec.gov/Archives/edgar/data/1847367/000184736726000016/alms-20260813x8k.htm) filed 2026-08-13 - [8-K](https://www.sec.gov/Archives/edgar/data/1847367/000110465926093353/tm2622655d1_8k.htm) filed 2026-08-10 - [8-K](https://www.sec.gov/Archives/edgar/data/1847367/000110465926080361/tm2619591d1_8k.htm) filed 2026-07-02 - [8-K](https://www.sec.gov/Archives/edgar/data/1847367/000110465926078507/tm2619143d1_8k.htm) filed 2026-06-29 - [DEF 14A](https://www.sec.gov/Archives/edgar/data/1847367/000110465926063223/tm266546-1_def14a.htm) filed 2026-05-18 - [10-Q](https://www.sec.gov/Archives/edgar/data/1847367/000184736726000010/alms-20260331x10q.htm) filed 2026-05-14 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001847367), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Alumis Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker ALMS, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Alumis Inc. - **Ticker**: ALMS - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Pharmaceuticals: Major - **ISIN**: US0223071020 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-ALMS/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/alumis/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Alumis (ALMS) news: class action, going concern and offering", 2026-10-31, https://aibio.space/companies/alumis/